VERIGRATE HEALTH · NEUROMODULATION

Private One-Day TMS

Private One-Day TMS

Private One-Day TMS

Verigrate Health is developing a physician-led one-day TMS program centered on major depressive disorder and integrated into a broader psychiatric treatment plan.

Verigrate Health is developing a physician-led one-day TMS program centered on major depressive disorder and integrated into a broader psychiatric treatment plan.

Coming soon. A treatment model built around one carefully planned day.

Coming soon. A treatment model built around one carefully planned day.

Inquire About One-Day TMS

Schedule Initial Consultation — $1,000

Explore the Dallas pathway →

Spacious wooden room with large glass windows and sunlight

ONE TREATMENT DAY

DIRECT PHYSICIAN OVERSIGHT

PRIVATE PAY

DALLAS + SELECT PRIVATE LOCATIONS

What is one-day TMS?

What is one-day TMS?

What is one-day TMS?

One-day TMS is an accelerated approach in which multiple transcranial magnetic stimulation sessions are delivered during a single structured treatment day.

One-day TMS is an accelerated approach in which multiple transcranial magnetic stimulation sessions are delivered during a single structured treatment day.

At Verigrate Health, the initial program is being developed for selected adults with major depressive disorder.

At Verigrate Health, the initial program is being developed for selected adults with major depressive disorder.

One-day TMS is considered within the patient’s broader diagnostic, medication, psychotherapeutic, metabolic, and longitudinal treatment context rather than as an isolated procedure.

One-day TMS is considered within the patient’s broader diagnostic, medication, psychotherapeutic, metabolic, and longitudinal treatment context rather than as an isolated procedure.

The Verigrate Health program is centered in Dallas, Texas, with private-location treatment planned for selected patients in eligible jurisdictions.

The Verigrate Health program is centered in Dallas, Texas, with private-location treatment planned for selected patients in eligible jurisdictions.

THE VERIGRATE MODEL

Treatment selected in context.

Treatment selected in context.

Treatment selected in context.

Verigrate Health is a specialized private psychiatry practice for complex treatment decisions. One-day TMS is considered within the patient’s complete clinical picture—including diagnosis, previous treatment response, medication exposure, adverse effects, withdrawal history, medical factors, psychotherapy, and longer-term goals.

Verigrate Health is a specialized private psychiatry practice for complex treatment decisions. One-day TMS is considered within the patient’s complete clinical picture—including diagnosis, previous treatment response, medication exposure, adverse effects, withdrawal history, medical factors, psychotherapy, and longer-term goals.

For some patients, appropriate care means carefully reducing medication burden. For others, active treatment remains necessary. TMS is one option when a different treatment approach may make sense. The practice is not built around a single treatment modality. Treatment is selected according to the patient’s clinical needs.

For some patients, appropriate care means carefully reducing medication burden. For others, active treatment remains necessary. TMS is one option when a different treatment approach may make sense. The practice is not built around a single treatment modality. Treatment is selected according to the patient’s clinical needs.

01

CLARIFY

Diagnosis, history, previous treatment, and clinical context.

Diagnosis, history, previous treatment, and clinical context.

02

RECONSIDER

Whether current treatment remains necessary, beneficial, proportionate, or burdensome.

Whether current treatment remains necessary, beneficial, proportionate, or burdensome.

03

TREAT

Medication, psychotherapy, metabolic approaches, or neuromodulation when clinically appropriate.

Medication, psychotherapy, metabolic approaches, or neuromodulation when clinically appropriate.

04

CONTINUE

One physician maintains the larger clinical picture over time.

One physician maintains the larger clinical picture over time.

THE TREATMENT DAY

One day, intentionally structured.

One day, intentionally structured.

One day, intentionally structured.

01

ARRIVE

Private intake, consent review, and final same-day readiness.

Private intake, consent review, and final same-day readiness.

02

CALIBRATE

Personalized targeting and dosing setup under physician direction.

Personalized targeting and dosing setup under physician direction.

03

TREAT

Accelerated stimulation blocks with interval safety checks.

Accelerated stimulation blocks with interval safety checks.

04

BETWEEN SESSIONS

Guided intervals with safety checks and environment control.

Guided intervals with safety checks and environment control.

05

COMPLETE

Day-end clinical review and follow-up planning.

Day-end clinical review and follow-up planning.

Weeks of repeated appointments vs. one carefully planned day.

Weeks of repeated appointments vs. one carefully planned day.

Weeks of repeated appointments vs. one carefully planned day.

CONVENTIONAL TMS

Repeated appointments across several weeks

Repeated appointments across several weeks

Multiple in-person clinic visits

Multiple in-person clinic visits

Recurring travel requirements

Recurring travel requirements

Potential work and family interruption

Potential work and family interruption

ONE-DAY TMS

Single-day accelerated schedule

Single-day accelerated schedule

One carefully planned treatment day

One carefully planned treatment day

Reduced repeated travel burden

Reduced repeated travel burden

Designed for selected patients

Designed for selected patients

No efficacy equivalence is claimed between schedules.

THE EVIDENCE

The evidence

The evidence

The evidence

Promising findings. Important limitations.

Conventional multi-week TMS has the most established evidence base for major depressive disorder using FDA-cleared systems. Accelerated approaches are a growing area with variable published findings across settings and populations, including smaller cohorts and still-developing randomized direct comparisons.

Conventional multi-week TMS has the most established evidence base for major depressive disorder using FDA-cleared systems. Accelerated approaches are a growing area with variable published findings across settings and populations, including smaller cohorts and still-developing randomized direct comparisons.

YEAR

2018

2018

STUDY DESIGN

Randomized controlled trial

Randomized controlled trial

SAMPLE SIZE

n = 414

n = 414

PUBLICATION

The Lancet

The Lancet

KEY FINDING

Compared two TMS schedules over 4–6 weeks rather than a one-day treatment schedule.

Compared two TMS schedules over 4–6 weeks rather than a one-day treatment schedule.

LIMITATION

Not a single-day protocol comparison and does not establish equivalence for a different planned program.

Not a single-day protocol comparison and does not establish equivalence for a different planned program.

View publication →

YEAR

2018

2018

STUDY DESIGN

Randomized comparison

Randomized comparison

SAMPLE SIZE

n = 115

n = 115

PUBLICATION

Neuropsychopharmacology

Neuropsychopharmacology

KEY FINDING

Compared accelerated treatment delivered over 3 weeks with standard treatment over 4 weeks.

Compared accelerated treatment delivered over 3 weeks with standard treatment over 4 weeks.

LIMITATION

Not single-day treatment; reported greater treatment discomfort and does not infer outcomes for a different planned program.

Not single-day treatment; reported greater treatment discomfort and does not infer outcomes for a different planned program.

View publication →

YEAR

2025

2025

STUDY DESIGN

Open-label case series

Open-label case series

SAMPLE SIZE

n = 32

n = 32

PUBLICATION

Transcranial Magnetic Stimulation

Transcranial Magnetic Stimulation

KEY FINDING

Reported symptom changes after a single-day regimen in an uncontrolled cohort.

Reported symptom changes after a single-day regimen in an uncontrolled cohort.

LIMITATION

Pharmacologic augmentation and no direct evidence that a different planned regimen produces the same outcomes.

Pharmacologic augmentation and no direct evidence that a different planned regimen produces the same outcomes.

View publication →

EMERGING SINGLE-DAY EVIDENCE

What has been reported in a real-world single-day case series?

What has been reported in a real-world single-day case series?

A 2025 retrospective, naturalistic, open-label case series reported outcomes in 32 adults with unipolar major depression who underwent an optimized single-day TMS regimen. The published treatment course consisted of 20 intermittent theta-burst stimulation (iTBS) sessions delivered approximately every 30 minutes over about 9.5 hours, together with pharmacologic augmentation.

CHARACTERISTICS OF THE PUBLISHED CASE SERIES — NOT A VERIGRATE TREATMENT PROMISE

32

ADULTS

20

TMS SESSIONS

9.5 hours

APPROXIMATE TREATMENT DAY

26 weeks

LONGEST REPORTED FOLLOW-UP

Reported outcomes at six weeks

On the clinician-rated HDRS-17 depression scale, the case series reported:

87.5%

RESPONSE · HDRS-17

71.9%

REMISSION · HDRS-17

Response was defined as at least 50% improvement. Remission was defined according to the study’s prespecified HDRS-17 threshold.

These percentages describe this uncontrolled case series and should not be interpreted as expected outcomes for an individual patient or as results Verigrate will reproduce.

TIME COURSE

Improvement was not immediate.

Improvement was not immediate.

In this case series, symptom improvement continued over the weeks following the treatment day rather than occurring primarily during the treatment itself. Average improvement generally approached a plateau around weeks 4–6.

A one-day treatment schedule does not necessarily mean a one-day clinical response.

What happened over longer follow-up?

At 12 weeks, the reported HDRS-17 response and remission rates remained 84.4% and 71.2%, respectively, using the original 32-patient sample as the denominator.

At approximately 26 weeks, 16 of the original 32 patients—50%—were classified as having sustained remission on both HDRS-17 and BDI-II.

By 26 weeks, some patients had relapsed or received retreatment, and some were lost to follow-up. These are preliminary durability observations, not a guarantee of lasting benefit.

Safety and tolerability in the case series

All 32 patients completed the 20-session treatment day.

No seizures, emergent mania or hypomania, or other serious adverse events were reported during treatment or the six-week safety follow-up in this small case series. This does not mean TMS is risk-free.

The most common treatment-related issue was discomfort. Mean scalp discomfort was approximately 5.8 on a 10-point scale. Transient headache or jaw discomfort was also reported.

INTERPRETING THE EVIDENCE

Promising findings. Important limitations.

Promising findings. Important limitations.

WHAT THIS STUDY ADDS

01 Practical feasibility of completing 20 TMS sessions in a single treatment day.

02 Real-world symptom observations from 32 adults with major depression.

03 Symptom follow-up through approximately six months and initial safety and tolerability observations.

04 A signal that improvement may continue over several weeks after treatment.

WHAT REMAINS UNCERTAIN

01 No sham or placebo control, no blinding, and a small sample.

02 Thirteen of 32 participants had previously responded to TMS.

03 Pharmacologic augmentation was used. The separate contributions of TMS, D-cycloserine, and lisdexamfetamine cannot be determined.

04 Results may not generalize to more severe or acute populations.

05 Long-term durability and optimal retreatment remain uncertain. Randomized controlled replication is needed.

The published regimen was not TMS alone.

The published single-day regimen included single-dose D-cycloserine 125 mg and lisdexamfetamine 20 mg before treatment as pharmacologic augmentation. These uses for TMS augmentation were off-label. The study cannot determine how much of the observed outcome was attributable to TMS, either medication, or their combination.

SOURCE & STUDY DISCLOSURES

Vaughn DA, Marino B, Engelbertson A, et al. Real-world effectiveness of a single-day regimen for transcranial magnetic stimulation using Optimized, Neuroplasticity-Enhanced techniques in Depression (ONE-D): An open-label case series. Transcranial Magnetic Stimulation. 2025;5:100200. doi:10.1016/j.transm.2025.100200

Several study authors disclosed employment, board, equity, consulting, patent, or other relationships with Ampa Health and other TMS-related organizations. Readers should consider these published disclosures alongside the observational study design. This is not an allegation of misconduct.

View publication and disclosures →

WHAT WE KNOW

Conventional multi-week TMS has deeper evidence maturity. Accelerated schedules show promising signals in selected research contexts.

Conventional multi-week TMS has deeper evidence maturity. Accelerated schedules show promising signals in selected research contexts.

WHAT REMAINS UNCERTAIN

How single-day outcomes compare directly with conventional pathways for broad patient populations remains uncertain, as does which patient subgroups are best suited for a one-day schedule.

How single-day outcomes compare directly with conventional pathways for broad patient populations remains uncertain, as does which patient subgroups are best suited for a one-day schedule.

Accelerated schedules continue to evolve, and outcomes vary across individuals. No outcome guarantees are made.

Accelerated schedules continue to evolve, and outcomes vary across individuals. No outcome guarantees are made.

Candidate selection and safety review

Candidate selection and safety review

Candidate selection and safety review

Candidacy is individualized through physician review of diagnosis context, previous care, implanted devices, neurologic history, and risk factors. Seizure risk is rare but possible and reviewed directly before scheduling.

Candidacy is individualized through physician review of diagnosis context, previous care, implanted devices, neurologic history, and risk factors. Seizure risk is rare but possible and reviewed directly before scheduling.

PRIVATE CARE, DESIGNED AROUND LOCATION

One treatment model. Three ways to receive care.

One treatment model. Three ways to receive care.

One treatment model. Three ways to receive care.

01

DALLAS

Private treatment at Verigrate Health in Preston Center, near the Park Cities.

Private treatment at Verigrate Health in Preston Center, near the Park Cities.

One-Day TMS in Dallas →

02

DFW CONCIERGE

For selected patients in Dallas–Fort Worth, an approved private residence or setting may be considered.

For selected patients in Dallas–Fort Worth, an approved private residence or setting may be considered.

03

NATIONAL CONCIERGE

Private-location treatment is planned for selected patients in eligible jurisdictions.

Private-location treatment is planned for selected patients in eligible jurisdictions.

Explore private-location care →

Christian S. Monsalve, M.D. holds medical licensure in 44 states and Washington, D.C. Mobile treatment availability is determined separately according to jurisdiction, clinical eligibility, safety, operations, and applicable requirements.

Christian S. Monsalve, M.D. holds medical licensure in 44 states and Washington, D.C. Mobile treatment availability is determined separately according to jurisdiction, clinical eligibility, safety, operations, and applicable requirements.

BEYOND A PROCEDURE

Less treatment when appropriate. Different treatment when necessary.

Less treatment when appropriate. Different treatment when necessary.

Less treatment when appropriate. Different treatment when necessary.

Verigrate Health has a particular clinical focus on psychiatric medication tapering and deprescribing. For some patients, carefully reducing burdensome treatment is appropriate; for others, persistent depression may warrant active treatment such as TMS. Medication changes are not automatic with TMS. The objective is proportionate treatment.

Verigrate Health has a particular clinical focus on psychiatric medication tapering and deprescribing. For some patients, carefully reducing burdensome treatment is appropriate; for others, persistent depression may warrant active treatment such as TMS. Medication changes are not automatic with TMS. The objective is proportionate treatment.

Explore precision medication tapering →

Neuromodulation beyond depression

Neuromodulation beyond depression

Neuromodulation beyond depression

TMS technology also has device- and protocol-specific applications beyond major depressive disorder. Verigrate evaluates neuromodulation according to diagnosis, available evidence, regulatory status, device capabilities, and individual clinical context.

TMS technology also has device- and protocol-specific applications beyond major depressive disorder. Verigrate evaluates neuromodulation according to diagnosis, available evidence, regulatory status, device capabilities, and individual clinical context.

Christian S. Monsalve, M.D.

YOUR PHYSICIAN

Meet your clinical lead

Meet your clinical lead

Meet your clinical lead

Christian S. Monsalve, M.D.

Christian S. Monsalve, M.D. is a board-certified psychiatrist and founder of Verigrate Health. His practice focuses on complex psychiatric consultation, diagnostic clarification, psychopharmacology, medication tapering and deprescribing, and individualized treatment planning. The one-day TMS program is being developed within the same physician-led, limited-panel model.

Christian S. Monsalve, M.D. is a board-certified psychiatrist and founder of Verigrate Health. His practice focuses on complex psychiatric consultation, diagnostic clarification, psychopharmacology, medication tapering and deprescribing, and individualized treatment planning. The one-day TMS program is being developed within the same physician-led, limited-panel model.

About Dr. Monsalve →

CLINICAL CONTENT REVIEWED BY

Christian S. Monsalve, M.D.

Board-Certified Psychiatrist · Founder & Medical Director, Verigrate Health

Last reviewed: September 2026

PRIVATE-PAY CARE

Anticipated investment

Anticipated investment

Anticipated investment

Estimated planning range is approximately $10,000–$20,000. Final fees may vary with treatment setting, travel, technician logistics, physician time, and clinical program structure. Final program structure and fees will be confirmed before treatment reservations are accepted.

Estimated planning range is approximately $10,000–$20,000. Final fees may vary with treatment setting, travel, technician logistics, physician time, and clinical program structure. Final program structure and fees will be confirmed before treatment reservations are accepted.

The standard $1,000 initial psychiatric consultation is the clinical entry point. Inquiries address fit, logistics, and availability—not individualized recommendations.

The standard $1,000 initial psychiatric consultation is the clinical entry point. Inquiries address fit, logistics, and availability—not individualized recommendations.

QUESTIONS

Frequently Asked Questions

Frequently Asked Questions

Frequently Asked Questions

ONE-DAY TMS · VERIGRATE HEALTH

The next step is a careful evaluation.

The next step is a careful evaluation.

The next step is a careful evaluation.

Coming soon. Inquiry is for questions, logistics, and preliminary interest. Scheduling starts formal clinical evaluation through the standard initial psychiatric consultation.

Coming soon. Inquiry is for questions, logistics, and preliminary interest. Scheduling starts formal clinical evaluation through the standard initial psychiatric consultation.

Inquire About One-Day TMS

Schedule Initial Consultation — $1,000